Joint effects of sodium and potassium intake on subsequent cardiovascular disease: The trials of hypertension prevention follow-up study

Nancy R. Cook, Eva Obarzanek, Jeffrey A. Cutler, Julie E. Buring, Kathryn M. Rexrode, Shiriki K. Kumanyika, Lawrence Appel, Paul K. Whelton

Research output: Contribution to journalArticle

Abstract

Background: Previous studies of dose-response effects of usual sodium and potassium intake on subsequent cardiovascular disease (CVD) have largely relied on suboptimal measures of intake. Methods: Two trials of sodium reduction and other interventions collected 24-hour urinary excretions intermittently during 18 months from September 17, 1987, to January 12, 1990 (Trials of Hypertension Prevention [TOHP] I), and during 36 months from December 18, 1990, to April 7, 1995 (TOHP II), among adults with prehypertension aged 30 to 54 years. Among adults not assigned to an active sodium reduction intervention, we assessed the relationship of a mean of 3 to 7 twenty-four-hour urinary excretions of sodium and potassium and their ratio with subsequent CVD (stroke, myocardial infarction, coronary revascularization, or CVD mortality) through 10 to 15 years of posttrial follow-up. Results: Among 2974 participants, follow-up information was obtained on 2275 participants (76.5%), with 193 CVD events. After adjustment for baseline variables and lifestyle changes, there was a nonsignificant trend in CVD risk across sex-specific quartiles of urinary sodium excretion (rate ratio [RR] from lowest to highest, 1.00, 0.99, 1.16, and 1.20; P=.38 for trend) and potassium excretion (RR, 1.00, 0.94, 0.91, and 0.64; P=.08 for trend) but a significant trend across quartiles of the sodium to potassium excretion ratio (RR, 1.00, 0.84, 1.18, and 1.50; P=.04 for trend). In models containing both measures simultaneously, linear effects were as follows: RR, 1.42; 95% confidence interval (CI), 0.99 to 2.04 per 100 mmol/24 h of urinary sodium excretion (P=.05); and 0.67; 0.41 to 1.10 per 50 mmol/24 h of urinary potassium excretion (P=.12). A model containing the sodium to potassium excretion ratio (RR, 1.24; 95% CI, 1.05-1.46; P=.01) had the lowest Bayes information criterion (best fit). Conclusion: A higher sodium to potassium excretion ratio is associated with increased risk of subsequent CVD, with an effect stronger than that of sodium or potassium alone.

LanguageEnglish (US)
Pages32-40
Number of pages9
JournalArchives of Internal Medicine
Volume169
Issue number1
DOIs
StatePublished - Jan 12 2009

Fingerprint

Potassium
Cardiovascular Diseases
Sodium
Hypertension
Myocardial Infarction
Prehypertension
Confidence Intervals
Coronary Disease
Life Style
Mortality

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Joint effects of sodium and potassium intake on subsequent cardiovascular disease : The trials of hypertension prevention follow-up study. / Cook, Nancy R.; Obarzanek, Eva; Cutler, Jeffrey A.; Buring, Julie E.; Rexrode, Kathryn M.; Kumanyika, Shiriki K.; Appel, Lawrence; Whelton, Paul K.

In: Archives of Internal Medicine, Vol. 169, No. 1, 12.01.2009, p. 32-40.

Research output: Contribution to journalArticle

Cook, Nancy R. ; Obarzanek, Eva ; Cutler, Jeffrey A. ; Buring, Julie E. ; Rexrode, Kathryn M. ; Kumanyika, Shiriki K. ; Appel, Lawrence ; Whelton, Paul K. / Joint effects of sodium and potassium intake on subsequent cardiovascular disease : The trials of hypertension prevention follow-up study. In: Archives of Internal Medicine. 2009 ; Vol. 169, No. 1. pp. 32-40.
@article{2aaf86a0089c4ccbab73c077637e0ded,
title = "Joint effects of sodium and potassium intake on subsequent cardiovascular disease: The trials of hypertension prevention follow-up study",
abstract = "Background: Previous studies of dose-response effects of usual sodium and potassium intake on subsequent cardiovascular disease (CVD) have largely relied on suboptimal measures of intake. Methods: Two trials of sodium reduction and other interventions collected 24-hour urinary excretions intermittently during 18 months from September 17, 1987, to January 12, 1990 (Trials of Hypertension Prevention [TOHP] I), and during 36 months from December 18, 1990, to April 7, 1995 (TOHP II), among adults with prehypertension aged 30 to 54 years. Among adults not assigned to an active sodium reduction intervention, we assessed the relationship of a mean of 3 to 7 twenty-four-hour urinary excretions of sodium and potassium and their ratio with subsequent CVD (stroke, myocardial infarction, coronary revascularization, or CVD mortality) through 10 to 15 years of posttrial follow-up. Results: Among 2974 participants, follow-up information was obtained on 2275 participants (76.5{\%}), with 193 CVD events. After adjustment for baseline variables and lifestyle changes, there was a nonsignificant trend in CVD risk across sex-specific quartiles of urinary sodium excretion (rate ratio [RR] from lowest to highest, 1.00, 0.99, 1.16, and 1.20; P=.38 for trend) and potassium excretion (RR, 1.00, 0.94, 0.91, and 0.64; P=.08 for trend) but a significant trend across quartiles of the sodium to potassium excretion ratio (RR, 1.00, 0.84, 1.18, and 1.50; P=.04 for trend). In models containing both measures simultaneously, linear effects were as follows: RR, 1.42; 95{\%} confidence interval (CI), 0.99 to 2.04 per 100 mmol/24 h of urinary sodium excretion (P=.05); and 0.67; 0.41 to 1.10 per 50 mmol/24 h of urinary potassium excretion (P=.12). A model containing the sodium to potassium excretion ratio (RR, 1.24; 95{\%} CI, 1.05-1.46; P=.01) had the lowest Bayes information criterion (best fit). Conclusion: A higher sodium to potassium excretion ratio is associated with increased risk of subsequent CVD, with an effect stronger than that of sodium or potassium alone.",
author = "Cook, {Nancy R.} and Eva Obarzanek and Cutler, {Jeffrey A.} and Buring, {Julie E.} and Rexrode, {Kathryn M.} and Kumanyika, {Shiriki K.} and Lawrence Appel and Whelton, {Paul K.}",
year = "2009",
month = "1",
day = "12",
doi = "10.1001/archinternmed.2008.523",
language = "English (US)",
volume = "169",
pages = "32--40",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Joint effects of sodium and potassium intake on subsequent cardiovascular disease

T2 - JAMA Internal Medicine

AU - Cook, Nancy R.

AU - Obarzanek, Eva

AU - Cutler, Jeffrey A.

AU - Buring, Julie E.

AU - Rexrode, Kathryn M.

AU - Kumanyika, Shiriki K.

AU - Appel, Lawrence

AU - Whelton, Paul K.

PY - 2009/1/12

Y1 - 2009/1/12

N2 - Background: Previous studies of dose-response effects of usual sodium and potassium intake on subsequent cardiovascular disease (CVD) have largely relied on suboptimal measures of intake. Methods: Two trials of sodium reduction and other interventions collected 24-hour urinary excretions intermittently during 18 months from September 17, 1987, to January 12, 1990 (Trials of Hypertension Prevention [TOHP] I), and during 36 months from December 18, 1990, to April 7, 1995 (TOHP II), among adults with prehypertension aged 30 to 54 years. Among adults not assigned to an active sodium reduction intervention, we assessed the relationship of a mean of 3 to 7 twenty-four-hour urinary excretions of sodium and potassium and their ratio with subsequent CVD (stroke, myocardial infarction, coronary revascularization, or CVD mortality) through 10 to 15 years of posttrial follow-up. Results: Among 2974 participants, follow-up information was obtained on 2275 participants (76.5%), with 193 CVD events. After adjustment for baseline variables and lifestyle changes, there was a nonsignificant trend in CVD risk across sex-specific quartiles of urinary sodium excretion (rate ratio [RR] from lowest to highest, 1.00, 0.99, 1.16, and 1.20; P=.38 for trend) and potassium excretion (RR, 1.00, 0.94, 0.91, and 0.64; P=.08 for trend) but a significant trend across quartiles of the sodium to potassium excretion ratio (RR, 1.00, 0.84, 1.18, and 1.50; P=.04 for trend). In models containing both measures simultaneously, linear effects were as follows: RR, 1.42; 95% confidence interval (CI), 0.99 to 2.04 per 100 mmol/24 h of urinary sodium excretion (P=.05); and 0.67; 0.41 to 1.10 per 50 mmol/24 h of urinary potassium excretion (P=.12). A model containing the sodium to potassium excretion ratio (RR, 1.24; 95% CI, 1.05-1.46; P=.01) had the lowest Bayes information criterion (best fit). Conclusion: A higher sodium to potassium excretion ratio is associated with increased risk of subsequent CVD, with an effect stronger than that of sodium or potassium alone.

AB - Background: Previous studies of dose-response effects of usual sodium and potassium intake on subsequent cardiovascular disease (CVD) have largely relied on suboptimal measures of intake. Methods: Two trials of sodium reduction and other interventions collected 24-hour urinary excretions intermittently during 18 months from September 17, 1987, to January 12, 1990 (Trials of Hypertension Prevention [TOHP] I), and during 36 months from December 18, 1990, to April 7, 1995 (TOHP II), among adults with prehypertension aged 30 to 54 years. Among adults not assigned to an active sodium reduction intervention, we assessed the relationship of a mean of 3 to 7 twenty-four-hour urinary excretions of sodium and potassium and their ratio with subsequent CVD (stroke, myocardial infarction, coronary revascularization, or CVD mortality) through 10 to 15 years of posttrial follow-up. Results: Among 2974 participants, follow-up information was obtained on 2275 participants (76.5%), with 193 CVD events. After adjustment for baseline variables and lifestyle changes, there was a nonsignificant trend in CVD risk across sex-specific quartiles of urinary sodium excretion (rate ratio [RR] from lowest to highest, 1.00, 0.99, 1.16, and 1.20; P=.38 for trend) and potassium excretion (RR, 1.00, 0.94, 0.91, and 0.64; P=.08 for trend) but a significant trend across quartiles of the sodium to potassium excretion ratio (RR, 1.00, 0.84, 1.18, and 1.50; P=.04 for trend). In models containing both measures simultaneously, linear effects were as follows: RR, 1.42; 95% confidence interval (CI), 0.99 to 2.04 per 100 mmol/24 h of urinary sodium excretion (P=.05); and 0.67; 0.41 to 1.10 per 50 mmol/24 h of urinary potassium excretion (P=.12). A model containing the sodium to potassium excretion ratio (RR, 1.24; 95% CI, 1.05-1.46; P=.01) had the lowest Bayes information criterion (best fit). Conclusion: A higher sodium to potassium excretion ratio is associated with increased risk of subsequent CVD, with an effect stronger than that of sodium or potassium alone.

UR - http://www.scopus.com/inward/record.url?scp=58349113188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58349113188&partnerID=8YFLogxK

U2 - 10.1001/archinternmed.2008.523

DO - 10.1001/archinternmed.2008.523

M3 - Article

VL - 169

SP - 32

EP - 40

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 1

ER -